# A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder

> **NCT00257075** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 267 (actual)

## Conditions studied

- Bipolar Disorders
- Manic Episode

## Interventions

- **DRUG:** Risperidone, oral tablets

## Key facts

- **NCT ID:** NCT00257075
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12
- **Primary completion:** —
- **Final completion:** 2002-05
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2011-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00257075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00257075, "A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00257075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*